-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Piper Sandler Adjusts Price Target on TCR2 Therapeutics to $10 From $8, Maintains Overweight Rating

Piper Sandler Adjusts Price Target on TCR2 Therapeutics to $10 From $8, Maintains Overweight Rating

MT Newswires · 01/06/2023 04:55